Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 14M | 13M | 13M | 13M | 19M |
| Gross Profit | 5M | 5M | 4M | 4M | 7M |
| Operating Income | -4M | -5M | -5M | -6M | -3M |
| EBITDA | -4M | -5M | -4M | -6M | -3M |
| Net Income | -3M | -5M | -5M | -5M | -4M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$1.15
+0.00% today
1Y Change
-62.24%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sonoma Pharmaceuticals, Inc. (SNOA) is a Healthcare stock with listed on NASDAQ. The stock last traded around $1.15 and down 62.2% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of +12.2%, EPS growth of +47.6%, a dividend yield of 0.0%. What stands out right now is revenue +12.2%, EPS +47.6%, free cash flow +93.0% with operating margin -15.6% and ROIC -28.3%. Valuation is more restrained than many high-expectation growth names at price/sales 0.1. Stock Foundry combines SNOA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SNOA
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SNOA Max Drawdown
-81.12%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SNOA and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$18.6M
+47.5% YoY
FY Net Income
-$4.0M
+22.3% YoY
Free Cash Flow
-$3.6M
+18.9% YoY
Revenue Growth
+12.2%
EPS Growth
+47.6%
Gross Margin
38.2%
Net Margin
-19.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 14M | 13M | 13M | 13M | 19M |
| Gross Profit | 5M | 5M | 4M | 4M | 7M |
| Operating Income | -4M | -5M | -5M | -6M | -3M |
| EBITDA | -4M | -5M | -4M | -6M | -3M |
| Net Income | -3M | -5M | -5M | -5M | -4M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 5M | 3M | 4M | 7M | 4M |
| Total Assets | 14M | 15M | 16M | 19M | 15M |
| Total Liabilities | 9M | 9M | 8M | 10M | 10M |
| Shareholder Equity | 4M | 6M | 8M | 9M | 5M |
| Total Debt | 305K | 608K | 849K | 1M | 3M |
| Net Debt | -5M | -3M | -3M | -6M | -2M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
3M
+20.5% YoY
Capital Expenditures
179K
-30.7% YoY
Free Cash Flow
4M
+18.9% YoY
Key ratios
Gross Margin
38.2%
Operating Margin
-15.6%
Net Margin
-19.0%
ROE
-85.9%
Debt / Equity
0.19x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.